Abbonarsi

Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma - 24/02/22

Doi : 10.1016/j.diii.2022.01.006 
Shamar Young a, ⁎, Tina Sanghvi b, Sandeep Sharma a, Cameron Richardson a, Nathan Rubin a, Masters Richards a, Donna D'Souza a, Siobhan Flanagan a, Jafar Golzarian a
a University of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA 
b Minneapolis VA Medical Center, Department of Radiology, MN, 55417, USA 

⁎Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Highlights

•
A significant proportion of patients with hepatocellular carcinoma who achieve complete radiologic response following transarterial chemoembolization will have local recurrence.
•
Variables such as liver function prior to transarterial chemoembolization and cause of underlying cirrhosis may predict local recurrence rates following complete response.
•
This study suggests that transarterial chemoembolization should be considered palliative and emphasizes the importance of long term follow up by interventional radiologists after treatment.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Purpose

The purpose of this study was to determine the local progression rate and identify factors that may predict local progression, in patients who achieve a complete response (CR) radiologically after undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC).

Materials and methods

One-hundred-forty-seven patients, who achieved CR of 224 HCCs after TACE, were retrospectively reviewed. There were 109 men and 38 women with a mean age of 61.6 ± 6.8 (SD) years (range: 45.4–86.9 years). Logistic mixed-effects and Cox regression models were used to evaluate associations between clinical factors and local progression.

Results

A total of 75 patients (75/147; 51%) and 99 (99/224,44.2%) lesions showed local progression at a median of 289.5 days (Q1: 125, Q3: 452; range: 51–2245 days). Pre-treatment, international normalization ratio (INR) (1.17 ± 0.15 [SD] vs. 1.25 ± 0.16 [SD]; P <0.001), model for end-stage liver disease (9.4 ± 2.6 [SD] vs. 10.6 ± 3.2 [SD]; P = 0.010) and Child-Pugh score (6 ± 1 [SD] vs. 6.4 ± 1.3 [SD]; P = 0.012) were significantly lower while albumin serum level (3.4 ± 0.62 [SD] vs. 3.22 ± 0.52 [SD]; P = 0.033) was significantly greater in those who showed local progression as compared to those who did not. In terms of local-recurrence free survival, the number of TACE treatments (hazard ratio [HR]: 2.05 [95% CI: 1.57–2.67]; P<0.001), INR (HR: 0.13 [95% CI: 0.03–0.61]; P = 0.010) and type of TACE (P = 0.003) were significant. Patients with local progression on any tumor did not differ from those who did in terms of overall survival (P = 0.072), however, were less likely to be transplanted (20/75, 26.7%) than those who did not (33/72; 36.1%) (P = 0.016).

Conclusion

A significant number of patients who achieve CR of HCC after TACE have local progression. This emphasizes the importance of long-term follow up.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : End stage liver disease, Interventional radiology, Hepatocellular carcinoma, Survival studies, Therapeutic chemoembolization


Mappa


© 2022  Société française de radiologie. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 103 - N° 3

P. 143-149 - marzo 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Structured and shared MRI staging lexicon and report of rectal cancer: A consensus proposal by the French Radiology Group (GRERCAR) and Surgical Group (GRECCAR) for rectal cancer
  • Stephanie Nougaret, Pascal Rousset, Kirsten Gormly, Oliver Lucidarme, Serge Brunelle, Laurent Milot, Cécile Salut, Franck Pilleul, Lionel Arrivé, Constance Hordonneau, Guillaume Baudin, Philippe Soyer, Vanessa Brun, Valérie Laurent, Celine Savoye-Collet, Iva Petkovska, Jean Pierre Gerard, Eric Rullier, Eddy Cotte, Philippe Rouanet, Regina G.H. Beets-Tan, Nora Frulio, Christine Hoeffel
| Articolo seguente Articolo seguente
  • External validation of a commercially available deep learning algorithm for fracture detection in children
  • Michel Dupuis, Léo Delbos, Raphael Veil, Catherine Adamsbaum

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.